The efficacy and safety of direct oral anticoagulants and vitamin K antagonists in the treatment of ATEs/VTEs in patients with MPNs was compared.
The risk for venous thromboembolism is steadily increasing among patients with cancer compared with the general population.
In a new study, researchers reported on the frequency of VTE among more than 6000 patients who tested positive for infection with SARS-CoV-2.
There might be notable variations among hematology, oncology, and bone marrow transplant practitioners when treating thrombotic events in children with leukemia.
Among some patients with cancer-associated thrombosis, rivaroxaban may be a viable alternative to low-molecular-weight heparin.
Researchers sought to markers that could identify high risk for splanchnic vein thrombosis among patients with MPNs.
In expanded research, investigators studied the effects of therapeutic and prophylactic anticoagulation treatment in hospitalized patients with COVID-19.
Despite thromboprophylaxis, patients who have newly developed multiple myeloma are at an “unacceptably high VTE risk”, study results suggest.
Growing concerns about thromboembolic comorbidities in patients with COVID-19 is leading ASH to create clinical practice guidelines to treat this patient population.
One finding from this study was that VTE was more likely to occur at atypical sites in patients with myelofibrosis compared to those without the disease.
